【摘要】 目的:评价三七粉与恩替卡韦(ETV)联用对乙肝患者肝纤维化的疗效及其对肝纤维化指标和肝脏硬度改善的影响。方法:选取2015年12月—2017年12月间收治的乙肝肝纤维化患者106例资料,按治疗方法的不同将其分为治疗组54例和对照组52例;对照组患者给予恩替卡韦抗病毒治疗,治疗组患者在对照组基础上加用三七粉治疗,比较两组患者治疗后的总有效率差异,以及治疗前后肝纤维化指标(透明质酸、层黏连蛋白、Ⅲ型前胶原、Ⅳ型胶原)与肝脏硬度水平测得值的变化情况。结果:治疗组患者治疗6月、1年时的总有效率均高于对照组(P<0.05);两组患者治疗前层黏连蛋白、透明质酸、Ⅲ型前胶原和IV型胶原水平测得值经组间比较其差异均无统计学意义(P>0.05),治疗后均低于治疗前(P<0.05);治疗组患者治疗6月和1年后的透明质酸、Ⅲ型前胶原水平测得值明显低于治疗前(P<0.05);治疗组患者治疗6月和1年后的肝脏硬度水平测得值低于对照组(P<0.05)。结论:采用三七粉与恩替卡韦抗病毒治疗肝纤维化患者的疗效优于单用恩替卡韦,有效改善了其肝纤维化指标与肝脏硬度。更多还原

【Abstract】 Objective:To evaluate the efficacy of Notoginseng powder combined with entecavir(ETV) in chronic hepatitis B(CHB) patients with liver fibrosis and its influence on liver fibrosis and liver hardness improvement. Methods:The data of 106 cases of CHB fibrosis patients admitted from December 2015 to December 2017 were divided into treatment group and control group according to different treatment methods, with 54 cases in each group. Control group patients was given ETV antiviral treatment, and the treatment group patients on the base of the control group were additionally given with Notoginseng powder. The differences of the total effective rate were compared. and the changes of the measured values of liver fibrosis indexes and liver stiffness level before and after the treatment(adhesion protein, hyaluronic acid, layer type Ⅲ before collagen and collagen type Ⅳ) were also compared. Results:The total effective rate of the treatment group was higher than that of the control group at 6 months and 1 year(P<0.05). In two groups of patients before treatment the layer adhesion protein, hyaluronic acid, collagen and collagen type IV level before Ⅲ type value could be measured by comparing the differences between two groups but they had no statistical significance(P>0.05); after treatment, it was lower than that before treatment(P<0.05). In treatment group patients at 6 months and 1 year the hyaluronic acid and collagen level before Ⅲ type measured value was lower than that before treatment(P<0.05) significantly. The liver hardness levels of the patients in the treatment group were lower than those in the control group at 6 months and 1 year after treatment(P<0.05). Conclusion:The efficacy of Notoginseng powder and entecavir in treating patients with liver fibrosis was better than that of using entecavir alone, and they effectively improved the indexes of liver fibrosis and liver hardness.更多还原